Drugmaker Mylan

A long-acting HIV jab promises near-perfect protection at just $40 a year, but 115 nations must wait for India's approval of generic production

Updated On: 30 Sep 2025 | 1:07 PM IST

The drug will be major contributor in the firm's bid to reach $1 billion revenue target by FY22, says biologics CEO Hamacher

Updated On: 12 Jun 2020 | 8:08 PM IST

Biocon Biologics, through its partner Mylan, has commercialised three of its co-developed biosimilars in developed markets like the US, Canada, the European Union and Australia.

Updated On: 27 Nov 2019 | 12:44 PM IST

US generic drugmakers such as Mylan and Teva Pharmaceutical Industries Ltd have suffered over the past few years as a steep fall in generic prices weighed on their bottom lines

Updated On: 06 Nov 2018 | 6:57 AM IST